A comprehensive Next Generation Sequencing (NGS) based test that detects cancer driving mutations for targeted selection and provides tools for immunotherapy recommendation.
- 364 genes in total, 38 sequenced from DNA & RNA
- Somatic Mutation Detection: SNV, indel, CNV and FUSION
- Immuno-oncology solutions for anti-PD1 Therapy recommendations: Microsatellite Instability (MSI), Tumor Mutation Burden (TMB) , HLA-typing
- Average depth of coverage exceeds 250x resulting in mutation detection with high specificity and sensitivity
|Suitable For:||Individuals diagnosed with cancer|
|Lab Certification:||CAP / CLIA|
|TAT:||14 – 21 working days upon receipt of sample at Laboratory|